Navigation Links
Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S.
Date:10/17/2011

PecFent® (fentanyl pectin nasal spray) in Europe, where it is presently available in six countries.  

"As the first and only treatment option in the U.S. offering fentanyl through nasal administration, Lazanda provides clinically proven pain relief to adult cancer patients suffering from breakthrough pain," noted Jeffrey H. Buchalter, chief executive officer of Archimedes Pharma. "The availability of Lazanda also is an exciting milestone for Archimedes Pharma as it marks our first product launch in the U.S. and represents the expansion of the brand from Europe."

Lazanda will be available through a Risk Evaluation and Mitigation Strategy (REMS) program, which is intended to minimize the risk of misuse, abuse, addiction, overdose, and serious complications due to medication errors. Under the Lazanda REMS program, pharmacies, distributors, and health care professionals who prescribe to outpatients are required to enroll in the program to dispense, distribute, and prescribe Lazanda.

About Lazanda® (fentanyl) nasal spray  Lazanda contains fentanyl, which is a Schedule II controlled substance, and uses Archimedes Pharma's patented drug delivery system, PecSys®.  

Lazanda, incorporating PecSys technology, delivers fentanyl in a rapid, but controlled manner and is designed to deliver a fine mist spray to a mucus membrane, in this case the nasal membrane.  Each spray of Lazanda forms a gel when it contacts the nasal mucosa; the active ingredient is then rapidly absorbed across the mucus membrane and directly into the blood stream.

The efficacy of Lazanda for the management of breakthrough pain in adult cancer patients was established in a double-blind, placebo-controlled clinical study in patients receiving opioid therapy for background pain, in which Lazanda showed a statistically significant improvement compared with placebo on the primary endpoint, the sum of the pain intensity differ
'/>"/>

SOURCE Archimedes Pharma Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Archimedes Pharma Announces Publication of Long-Term Safety and Tolerability Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in the Journal of Opioid Management
2. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
3. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
4. Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
5. Novo Nordisk A/S: PharmaVitae Profile
6. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
7. Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES
8. Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors
9. Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
10. CVS/pharmacy Ready to Provide Assistance During Medicare Part D Annual Enrollment Period
11. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , April 22 Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: ... (LOI) to acquire DMI Biosciences, Inc. , ... This acquisition will give AMPIO access to all rights, royalties ... licensed to a specialty pharmaceutical company after demonstrating safety and efficacy in ...
... ,, HARBIN, China , ... ("Renhuang" or the "Company"), a,developer, manufacturer and distributor of botanical ... has significantly reduced its Days Sales Outstanding ("DSO"),resulting in improved ... , , ...
Cached Medicine Technology:Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc. 2Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc. 3Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding 2Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding 3Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding 4
(Date:4/17/2014)... in PLOS Pathogens , children who live in ... mount an immune response to infection with malaria parasites ... high fever and illness and partially control the growth ... help researchers develop future interventions that prevent or mitigate ... year, approximately 200 million cases of malaria occur worldwide, ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood ... at UC Irvine and the Salk Institute have opened ... prevent stroke-induced brain damage. , A complex and devastating ... and primary reason for disability in the U.S. The ... lets blood-borne material into the brain, causing the permanent ...
(Date:4/17/2014)... online has the potential to ward off depression among ... research published online in The Journals of ... . In the article " Internet Use and Depression ... Longitudinal Analysis ," the authors report that Internet use ... percent among their study sample. , Late-life depression ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... Annapolis Media ... Event, ANNAPOLIS, Md., Sept. ... will have used,an inhalant by the 8th grade. In Maryland, inhalant use is ... are,the drug of choice, with use rates over twice the rate of marijuana ...
... 28 With audience members cheering and,famous Chicago chefs ... cooker for the finalists at Consorta,s Battle of the ... as the organic cucumbers he,serves the patients at Saint ... the event,s Gold Chef Award, becoming the reigning champion ...
... "Tonight the candidates,lost an opportunity to engage in ... dominate people,s day to day lives. (Logo: ... in the African American,community, with one in four adults ... able to afford to retire. "With just one ...
... has recently inspired research into its therapeutic value ... prevention. A painful, progressive autoimmune disease, rheumatoid ... of depressiondouble the risk of the healthy population, ... Increasingly, RA patients are turning to alternative ...
... raised in bilingual homes learned two similar-sounding words in a ... raised in homes where only one language is spoken. This ... appears to be due to the fact that bilingual babies ... words and objects (often a word in each language) for ...
... In a victory for the,families of small business ... legislation that will improve accessibility of the State,Children,s ... and Olympia Snowe (R-Maine) attached an amendment to ... to enroll more,children in the program. The provision ...
Cached Medicine News:Health News:National Battle of the Hospital Chefs Cooks Up a Winner 2Health News:Post-Debate Statement from AARP Board Member Joyce Payne 2Health News:Meditation therapy for rheumatoid arthritis patients 2Health News:Meditation therapy for rheumatoid arthritis patients 3Health News:Babies raised in bilingual homes learn new words differently than infants learning one language 2Health News:Babies raised in bilingual homes learn new words differently than infants learning one language 3Health News:Bipartisan Bill Expands Health Care Access for Small Businesses 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: